Flow cytometric analysis of B7-H4 expression on SK-BR-3 cells. Cells from the SK-BR-3 (Human breast adenocarcinoma epithelial cell, Right) or HeLa (Human cervix adenocarcinoma epithelial cell, Left) was stained with either APC Mouse IgG1, κ Isotype Control (Black line histogram) or SDT APC Mouse Anti-Human B7-H4 Antibody (Red line histogram) at 1.25 μl/test, cells without incubation with primary antibody and secondary antibody (Blue line histogram) was used as unlabelled control. Flow cytometry and data analysis were performed using BD FACSymphony™ A1 and FlowJo™ software.
APC Mouse Anti-Human B7-H4 Antibody (S-3024)
APC Mouse Anti-Human B7-H4 Antibody (S-3024)
Price:
Regular price
$155 USD
Regular price
Sale price
$155 USD
Unit price
per
For shipping services or bulk orders, you may request a quotation.
Secure checkout with
View full details
Product Details
Product Details
Product Specification
| Host | Mouse |
| Antigen | B7-H4 |
| Synonyms | V-set domain-containing T-cell activation inhibitor 1; B7 homolog 4 (B7-H4); B7h.5; Immune costimulatory protein B7-H4; Protein B7S1; T-cell costimulatory molecule B7x; B7H4; VTCN1 |
| Location | Cell membrane |
| Accession | Q7Z7D3 |
| Clone Number | S-3024 |
| Antibody Type | Mouse mAb |
| Isotype | IgG1,k |
| Application | FCM |
| Reactivity | Hu |
| Positive Sample | SK-BR-3 |
| Purification | Protein G |
| Concentration | 0.2 mg/ml |
| Conjugation | APC |
| Physical Appearance | Liquid |
| Storage Buffer | PBS, 1% BSA, 0.3% Proclin 300 |
| Stability & Storage | 12 months from date of receipt / reconstitution, 2 to 8 °C as supplied |
Dilution
| application | dilution | species |
| FCM | 1.25μl per million cells in 100μl volume | Hu |
Background
B7-H4, also known as VTCN1 or B7x, is a ~50 kDa type-I trans-membrane glycoprotein of the B7 immunoglobulin superfamily that consists of an extracellular IgV-IgC domain pair, a single trans-membrane segment and a short cytoplasmic tail; it is expressed inducibly on antigen-presenting cells and constitutively on many epithelial cancers, where it acts as an immune-checkpoint ligand by binding an as-yet-unidentified receptor on activated CD4⁺ and CD8⁺ T cells, thereby arresting the cell cycle in G0/G1, suppressing IL-2 production and proliferation, and enabling tumours to evade immunity, making it an emerging target for cancer immunotherapy.
Picture
Picture
FC
